Anti-Human CD8 [Clone UCHT-4] — Purified in vivo PLATINUM™ Functional Grade

Clone UCHT-4 is a monoclonal antibody targeting human CD8, and in mice, it is commonly used in humanized mouse models for several in vivo immunological applications.

The most frequent in vivo applications of UCHT-4 in mice include:

• Identification and tracking of human CD8+ T cells: UCHT-4 is used to specifically label human CD8+ T cells in mice reconstituted with human immune systems, allowing researchers to monitor the presence, localization, and migration of these cells during experiments.
• Functional modulation and depletion of human CD8+ T cells: UCHT-4 can be administered to selectively deplete or functionally modulate human CD8+ T cells in vivo to investigate their roles in immune responses, such as tumor immunity, infection models, graft-versus-host disease, and other T-cell-related processes.
• Assessment of CD8+ T cell activity in humanized models: This antibody is instrumental in studies of T cell-mediated cytotoxicity, vaccine responses, and immune modulation, where the activity of human CD8+ T cells in murine models needs to be analyzed or manipulated.

Key details:

• UCHT-4 is mouse IgG2a isotype and reacts specifically with human, not murine, CD8.
• Its use is restricted to "humanized" mouse models—mice engrafted with human immune cells—because it does not recognize mouse CD8.
• Applications are centered on preclinical studies, such as immuno-oncology, infection, and tolerance, where the function of human CD8+ T cells must be precisely controlled in vivo.

In summary, UCHT-4 is primarily used for identification, depletion, and functional modulation of human CD8+ T cells in humanized mice for immunological research.

Commonly used antibodies or proteins with UCHT-4 (a monoclonal anti-human CD8 antibody) in the literature include other antibodies that help distinguish different immune cell populations or define specific cell phenotypes in flow cytometry and immunological assays.

Key antibodies and proteins frequently used with UCHT-4:

• Anti-CD3 antibodies (such as UCHT1 or OKT3): Used to identify total T cells (CD3+), as CD8 is a co-receptor expressed on a T cell subset.
• Anti-CD4 antibodies: These are used to define the CD4+ T cell population, typically combined in panels with anti-CD8 (UCHT-4) for T cell subset analysis.
• Anti-CD19: Often used in combination to distinguish T cells (CD3+, CD8+) from B cells (CD19+), especially in mixed lymphocyte or PBMC (peripheral blood mononuclear cell) assays.
• Anti-CD45: A pan-leukocyte marker often used in gating strategies alongside CD8 (UCHT-4) to define total leukocytes and T cell subsets.
• Anti-CD16, Anti-CD56: NK cell markers that may be paired with UCHT-4 to discriminate NK cells (CD16+, CD56+) from CD8+ cytotoxic T cells.
• Other markers: Depending on study focus, markers such as anti-CD25 (activation marker), anti-CD14 (monocyte marker), and viability dyes can also be present in multi-color panels involving UCHT-4.

Summary table of common markers used with UCHT-4 (anti-CD8):

These antibody combinations are central to immunophenotyping in flow cytometry, immune monitoring, and basic immunology research.

Clone UCHT-4 is a monoclonal antibody used to detect human CD8, a surface marker predominantly present on cytotoxic T cells and some regulatory T cell subsets. The key findings from scientific literature that cite clone UCHT-4 center on its value for identifying and isolating CD8+ T cells in immunology research and clinical diagnostic applications.

Key findings from UCHT-4 citations include:

• Highly specific for human CD8 antigen: UCHT-4 reliably binds the CD8 marker, allowing detection of cytotoxic T cells in various samples, facilitating research in immunophenotyping, immune monitoring, and flow cytometry.
• Used for cell sorting and immune profiling: Due to its specificity, UCHT-4 is a common reagent for identifying and isolating CD8+ T cells, enabling downstream functional, genetic, or proteomic analyses of these subsets.
• Clinical and research relevance: The antibody supports studies of immune responses in infection, cancer, and autoimmune diseases by enabling quantification and characterization of CD8+ cells.

Citations of UCHT-4 commonly highlight its reliability and effectiveness in flow cytometry, immunohistochemistry, and related immunological assays. The literature does not report significant limitations or cross-reactivity issues, consolidating its reputation as a standard tool for CD8 detection.

No contradictory findings regarding the function or specificity of clone UCHT-4 are apparent in the cited scientific literature. If you require more specific or recent findings from individual studies, please specify the application or context of interest.

Dosing regimens for clone UCHT-4 anti-human CD8 antibody can vary depending on the specific mouse model and experimental context, but direct published data on precise dosing schedules for UCHT-4 across mouse models is limited. Most protocols rely on empirically determined dosing based on the mouse model, the desired level of CD8+ cell depletion, and the immunological environment.

There are several key factors influencing regimen selection:

• Mouse strain and immune status: Immunodeficient vs. immunocompetent strains may respond differently due to their baseline CD8+ T cell populations.
• Type of humanized mouse model: NSG (NOD-scid IL2Rgamma null) mice, for instance, are commonly used for engraftment with human immune cells; dosing may need adjusting to balance efficacy and toxicity for the human cells present.
• Experimental aim: For complete depletion, higher or more frequent doses may be used, while partial depletion or functional modulation may require less.
• Antibody source and formulation: Purity, functional grade, and batch differences affect dosing.

General empirical guidance for anti-CD8 depletion in mouse models (based on analogous clone protocols, as specific published UCHT-4 regimens are rare):

• Typically, intraperitoneal injection of 200–250 μg per mouse, administered 2–3 times per week, achieves robust depletion in immunocompetent models for anti-mouse CD8 clones.
• For anti-human CD8 clones in humanized mice, initial pilot experiments are recommended to titrate the antibody dose. Dosing is often started in the range of 100–250 μg per mouse per dose.
• Humanized mice with human CD8+ T cells (e.g., NSG, NSG-HuPBMC, or NSG-HuCD34+) may require tailored regimens to optimize selective depletion while minimizing off-target effects.

Variation Across Models:

• Humanized NSG mice: Lower doses and delayed schedules may be used due to higher sensitivity and slower clearance rates, with monitoring of depletion efficacy by flow cytometry.
• Standard C57BL/6 or BALB/c mice engrafted with human cells: May tolerate higher or more frequent dosing, but pilot studies are essential.

No universal regimen applies, so researchers are advised to:

• Start with 100–250 μg per mouse intraperitoneally, adjusting based on cell depletion assays.
• Consider weekly vs. biweekly dosing, depending on antibody half-life and immune reconstitution rates.

If the context specifically requires clone UCHT-4, and published protocols are unavailable, contacting suppliers (e.g., Leinco Technologies) for technical guidance or referencing closely related clones (e.g., OKT-4, RPA-T4) is recommended.

In summary, clone UCHT-4 dosing regimens vary by mouse model, immune context, and experimental aim, with empirical titration needed for humanized settings. Published literature offers protocols for mouse anti-CD4 or anti-CD8 analogs, but direct UCHT-4 schedules are rarely specified.